Collectively, these results and the significant correlation of FAM189A2 downregulation with the poor long‐term prognosis of breast cancer patients illustrate that FAM189A2 is a new activator for ITCH that impacts the biology of cancer cells by regulating the CXCR4 desensitization process. Here, CXCR4 is linked to breast cancer.